Table 4. Correlation of PGC-1 expression with clinicopathological features of GC.
| Groups | n | PGC-1 expression |
Positive rate (%) | χ2 | P | |||
|---|---|---|---|---|---|---|---|---|
| – | + | ++ | +++ | |||||
| Gender | 0.224 | 0.636 | ||||||
| Female | 54 | 26 | 22 | 6 | 0 | 51.85 | ||
| Male | 125 | 65 | 50 | 9 | 1 | 48.00 | ||
| Age (year) | 0.006 | 0.937 | ||||||
| ≤61 | 88 | 45 | 37 | 6 | 0 | 48.86 | ||
| >61 | 91 | 46 | 35 | 9 | 1 | 49.45 | ||
| Borrmann’s types | 1.058 | 0.219 | ||||||
| Bor I & II | 24 | 15 | 7 | 2 | 0 | 37.50 | ||
| Bor III & IV | 155 | 76 | 65 | 13 | 1 | 50.97 | ||
| WHO’s histological types | <0.001 | |||||||
| Papillary ade. | 2 | 0 | 2 | 0 | 0 | 100.00 | ||
| Well-diff. ade. | 13 | 2 | 10 | 1 | 0 | 84.62 | <0.001* | |
| Moderately-diff. ade. | 68 | 26 | 30 | 11 | 1 | 61.76 | ||
| Poorly-diff. ade. | 73 | 51 | 20 | 2 | 0 | 30.14 | ||
| Undiff. car. | 4 | 2 | 2 | 0 | 0 | 50.00 | ||
| Mucinous ade. | 15 | 10 | 4 | 1 | 0 | 33.33 | ||
| SRC | 4 | 0 | 4 | 0 | 0 | 100.00 | ||
| Lauren’s types | 18.121 | <0.001 | ||||||
| Intestinal | 83 | 28 | 42 | 12 | 1 | 66.27 | ||
| Diffuse | 81 | 53 | 26 | 2 | 0 | 34.57 | ||
| Mixed | 15 | 10 | 4 | 1 | 0 | 33.33 | ||
| Lymph node metastasis | 1.692 | 0.193 | ||||||
| No | 52 | 23 | 23 | 5 | 1 | 55.77 | ||
| Yes | 127 | 68 | 49 | 10 | 0 | 46.46 | ||
| Clinical stage | Fisher | 0.642 | ||||||
| I-II | 65 | 30 | 30 | 5 | 0 | 53.85 | ||
| III-IV | 114 | 61 | 42 | 10 | 1 | 46.49 | ||
ade., adenocarcinomas; diff., differentiated; car., carcinoma; *, expression of PGC-1 decreases from well-, through moderately-, to poorly-diff. ade., rk=–0.358. PGC-1, peroxisome proliferator-activated receptor-gamma coactivator-1; GC, gastric carcinoma; SRC, signet ring cell carcinomas.